CollPlant Shares Soar 5.59% on Milestone Payment, Earnings

CollPlant Biotechnologies Ltd. (CLGN) shares surged 5.59% in pre-market trading on May 29, 2025, driven by a series of positive developments and financial results.

CollPlant Biotechnologies Ltd. has reported significant progress in its core programs and a notable financial turnaround in its first-quarter financial report for 2025. The company received a $2 million milestone payment from its partner AbbVie, marking a key development achievement in their ongoing collaboration. This payment significantly contributed to the company's revenue growth, which reached $2.1 million compared to $98,000 in the same period of 2024. The company also noted a decrease in operating expenses, attributed to a cost reduction plan, which helped reduce the net loss to $1.5 million from $4.2 million in the previous year.

CollPlant's advancements in its regenerative breast implant program and photocurable dermal filler candidate are progressing towards clinical stages. The company is optimistic about its future, with plans to continue optimizing its regenerative breast implants for long-term tissue remodeling and durability. CollPlant’s management remains focused on advancing its core programs while maintaining a disciplined approach to cost management, aiming to position the company as a leader in the regenerative medicine space.

Looking ahead, CollPlant’s management is committed to pursuing strategic initiatives that support a well-capitalized path forward, with a focus on non-dilutive transactions to benefit shareholders. The company is poised to continue its innovative work in regenerative medicine and aesthetics, leveraging its proprietary rhCollagen technology to address unmet needs in the market.